136 related articles for article (PubMed ID: 18584582)
1. Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension.
Grassi G; Quarti-Trevano F; Mancia G
J Renin Angiotensin Aldosterone Syst; 2008 Jun; 9(2):66-74. PubMed ID: 18584582
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes.
Cao Z; Cooper ME
Acta Diabetol; 2012 Aug; 49(4):243-54. PubMed ID: 21947383
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan: just an antihypertensive agent? A literature review.
Destro M; Cagnoni F; Dognini GP; Galimberti V; Taietti C; Cavalleri C; Galli E
Expert Opin Pharmacother; 2011 Dec; 12(17):2719-35. PubMed ID: 22077832
[TBL] [Abstract][Full Text] [Related]
4. Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?
Weber M
J Hypertens Suppl; 2009 Jul; 27(5):S9-14. PubMed ID: 19587555
[TBL] [Abstract][Full Text] [Related]
5. Telmisartan in high-risk cardiovascular patients.
Weber MA
Am J Cardiol; 2010 Jan; 105(1 Suppl):36A-43A. PubMed ID: 20102972
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.
Kishi T; Hirooka Y; Konno S; Sunagawa K
J Hypertens; 2012 Aug; 30(8):1646-55. PubMed ID: 22728908
[TBL] [Abstract][Full Text] [Related]
7. The ONTARGET/TRANSCEND Trial Programme: baseline data.
Sleight P
Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
[TBL] [Abstract][Full Text] [Related]
8. Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan.
Chrysant SG; Chrysant GS; Desai A
J Hum Hypertens; 2005 Mar; 19(3):173-83. PubMed ID: 15660122
[TBL] [Abstract][Full Text] [Related]
9. Telmisartan and cardioprotection.
Akhrass PR; McFarlane SI
Vasc Health Risk Manag; 2011; 7():677-83. PubMed ID: 22140319
[TBL] [Abstract][Full Text] [Related]
10. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL;
Am J Cardiol; 2009 Dec; 104(11):1484-9. PubMed ID: 19932779
[TBL] [Abstract][Full Text] [Related]
11. Renin-angiotensin system blockade and cardiovascular and renal protection.
Hoogwerf BJ
Am J Cardiol; 2010 Jan; 105(1 Suppl):30A-5A. PubMed ID: 20102971
[TBL] [Abstract][Full Text] [Related]
12. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
13. Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?
Neldam S
Future Cardiol; 2010 Jan; 6(1):129-35. PubMed ID: 20014992
[TBL] [Abstract][Full Text] [Related]
14. Telmisartan: a different angiotensin II receptor blocker protecting a different population?
Burnier M
J Int Med Res; 2009; 37(6):1662-79. PubMed ID: 20146864
[TBL] [Abstract][Full Text] [Related]
15. Hypertension treatment and implications of recent cardiovascular outcome trials.
Weber MA
J Hypertens Suppl; 2006 Apr; 24(2):S37-44. PubMed ID: 16601560
[TBL] [Abstract][Full Text] [Related]
16. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
Yamagishi S; Takenaka K; Inoue H
Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
[TBL] [Abstract][Full Text] [Related]
17. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J
Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876
[TBL] [Abstract][Full Text] [Related]
18. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
Mori Y; Tanaka T; Matsuura K; Yokoyama J; Utsunomiya K
Adv Ther; 2011 Aug; 28(8):698-706. PubMed ID: 21744143
[TBL] [Abstract][Full Text] [Related]
19. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
Yu LT; Zhu J; Tan HQ; Wang GG; Teo KK; Liu LS
Chin Med J (Engl); 2011 Jun; 124(12):1763-8. PubMed ID: 21740829
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
